The US is fast-tracking this important HIV drug — for everyone except South Africa

But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...
The American Journal of Managed Care

Different Communication of HIV Risk Affects PrEP Interest

Encouraging the use of pre-exposure prophylaxis (PrEP) depends on the way that HIV risk is communicated to subgroups that are traditionally at the highest risk. A new study found that interest in PrEP ...

NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Health Affairs

Follow-On Cancer Drugs Target Earlier Stages Than Initial Drugs: Implications Of The IRA

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
Stocktwits on MSN

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck gets EU nod for subcutaneous version of Keytruda

Merck's Keytruda wins EU approval for a new injectable form, offering greater treatment options for adults. Read more here.

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3.

Judges signal Tylenol-autism case revival

Federal judges signaled a willingness Monday to overrule a lower-court judge who rejected cases lodged by families claiming ...

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...